AVG Meeting on ‘Clinical Trial Endpoints for Studies of Antivirals in Hospitalised and At-Risk Influenza Patients’

5.30-8.30pm, Sunday 8th September 2013

Room 1.41, CTICC

AGENDA

Welcome from the Chairs – Frederick Hayden, University of Virginia, Charlottesville, United States and Maria Zambon, Public Health England, London, United Kingdom

Virologic Endpoints and Sampling Strategies in Influenza Patients
Michael Ison, Northwestern University, Illinois, United States

Correlations of Virologic Measures and Clinical Endpoints in Hospitalised Patients
Nelson Lee, The Chinese University of Hong Kong, Hong Kong

Clinical Endpoints and Predictors of Outcomes in Hospitalised Patients during the 2009 Pandemic
Jonathan Van-Tam, University of Nottingham, Nottingham, United Kingdom

Experience with Virologic Measures and Clinical Endpoints in Phase 2 and 3 Studies of Intravenous Peramivir in Hospitalized Influenza Patients
Michael Ison, Northwestern University, Illinois, United States (on behalf of BioCryst and the Peramivir Development Program)

Challenges of study design in hospitalised patients with flu: the IV zanamivir experience
Helen Steel, GlaxoSmithKline, Middlesex, United Kingdom

Discussants
WHO Perspectives
Nikki Shindo, World Health Organization, Geneva, Switzerland

Specific Issues in pregnancy
Shigeru Saito, University of Toyama, Toyama Prefecture, Japan

Future Directions
Meeting Chairs

Close of Meeting and Refreshments